Generic Watch
Tracking 25 brand-name drugs by patent expiration date. 10 are expiring within the next 3 years, representing $36.1B in Medicare spending. When generics launch, prices typically drop 80-95%.
Expiring Within 3 Years
| Drug | Cost/Claim | Patent Expires | Time Left |
|---|---|---|---|
| Januvia Sitagliptin | $219.00 | Jul 17, 2026 | 0mo |
| Trintellix Vortioxetine | $278.00 | Sep 30, 2026 | 3mo |
| Entresto Sacubitril/Valsartan | $379.00 | Nov 11, 2026 | 4mo |
| Revlimid Lenalidomide | $12,786.00 | Mar 15, 2027 | 8mo |
| Pomalyst Pomalidomide | $17,250.00 | Apr 9, 2027 | 9mo |
| Trulicity Dulaglutide | $473.00 | Sep 18, 2027 | 1.2yr |
| Gilenya Fingolimod | $5,738.00 | Sep 22, 2027 | 1.2yr |
| Jakafi Ruxolitinib | $11,432.00 | Nov 16, 2027 | 1.3yr |
| Keytruda Pembrolizumab | $18,176.00 | Jun 28, 2028 | 2.0yr |
| Basaglar Insulin Glargine (biosimilar) | $130.00 | Dec 16, 2028 | 2.4yr |
Patent Protected (3+ Years)
| Drug | Cost/Claim | Patent Expires | Time Left |
|---|---|---|---|
| Repatha Evolocumab | $757.00 | Aug 27, 2029 | 3.1yr |
| Vraylar Cariprazine | $383.00 | Sep 17, 2029 | 3.2yr |
| Enbrel Etanercept | $1,726.00 | Nov 2, 2029 | 3.3yr |
| Venclexta Venetoclax | $6,784.00 | Apr 11, 2030 | 3.8yr |
| Trelegy Ellipta Fluticasone/Umeclidinium/Vilanterol | $380.00 | Sep 26, 2030 | 4.2yr |
| Harvoni Ledipasvir/Sofosbuvir | $24,958.00 | Oct 10, 2030 | 4.3yr |
| Dupixent Dupilumab | $2,819.00 | Mar 28, 2031 | 4.7yr |
| Breztri Aerosphere Budesonide/Glycopyrrolate/Formoterol | $305.00 | Jul 24, 2031 | 5.0yr |
| Ozempic Semaglutide | $685.00 | Sep 20, 2031 | 5.2yr |
| Fasenra Benralizumab | $2,836.00 | Nov 14, 2031 | 5.3yr |
| Tagrisso Osimertinib | $11,591.00 | Nov 13, 2032 | 6.3yr |
| Biktarvy Bictegravir/Emtricitabine/TAF | $3,746.00 | Feb 7, 2033 | 6.6yr |
| Rinvoq Upadacitinib | $3,498.00 | Aug 16, 2033 | 7.1yr |
| Skyrizi Risankizumab | $4,475.00 | Apr 23, 2035 | 8.8yr |
| Mounjaro Tirzepatide | $673.00 | May 13, 2036 | 9.8yr |
Frequently Asked Questions
Generic drugs typically cost 80-95% less than the brand-name original. Prices usually drop within 6-12 months of the first generic launch and continue falling as more manufacturers enter the market.
Januvia (Sitagliptin) has the earliest patent expiration among tracked drugs, set for Jul 17, 2026. It currently treats diabetes and costs $219.00 per claim.
Drugs expiring within the next 3 years represent $36.1B in annual Medicare Part D spending. Generic competition typically erodes that spending sharply once manufacturers enter the market.
When a primary patent expires, any FDA-approved generic manufacturer can enter the market. The first generic often launches within weeks of patent expiration, and once multiple generics are available, prices typically drop to a fraction of the original brand price.
Related
Patent expiration dates reflect the earliest relevant patent on file in the FDA Orange Book. Actual generic launch timing can vary due to litigation, additional patents, and exclusivity periods.
Track Generic Launches
Get new drug-price rankings by email. No spam, unsubscribe anytime.